Journal Information
Full text access
Pre-proof, online 18 June 2025
Risk Validation Of A New Quantitative Score For Clinical Control Of Chronic Obstructive Pulmonary Disease: The Radar Score
Visits
5
JJ Soler-Cataluña1,2,
Corresponding author
juan.j.soler@uv.es

Correspondence: Servicio de Neumología, Hospital Arnau de Vilanova-Lliria, C/ San Clemente 12, 46015 Valencia, Spain
, Villagrasa M1, P Catalán1, B Alcazar-Navarrete3,2, M Calle Rubio4,2, M Miravitlles5,2
1 Pulmonary Department. Hospital Arnau de Vilanova-Lliria, Valencia. Medicine Departament, Valencia University, Valencia, Spain
2 Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain
3 Pulmonary Department, Hospital Virgen de las Nieves, Granada. IBS-Granada, Medicine Department, Universidad de Granada, Granada, Spain
4 Pulmonary Department Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos. Departamento de Medicina, Universidad Complutense de Madrid, Spain
5 Pulmonary Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
This item has received
Article information
Abstract

Objective: Clinical control has been proposed as a composite endpoint in chronic obstructive pulmonary disease (COPD), assessable through the COPD Clinical Control Questionnaire (CCOq). A new score, derived from the CCOq, and termed as RADAR (Rescue medication, Acute exacerbations, Dyspnea, physical Activity, and Risk) has been developed. This study aimed to validate the RADAR score by analyzing its predictive value for future risk and health status.

Methods: A 12-month prospective observational study was conducted in stable COPD patients. Clinical control was assessed at 3 months using both the CCOq and the RADAR score (range 0–8). Dyspnea was evaluated both adjusted and unadjusted for FEV₁%. The primary outcome was time to the first composite event (emergency visit, COPD hospitalization, or all-cause mortality); the secondary outcome was the COPD Assessment Test (CAT) score at 12 months.

Results: Of 265 patients enrolled (16.2% women; mean age: 68 ± 9 years; FEV₁%: 58 ± 17), 239 completed the 3-month assessment. Among patients with RADAR scores of 0–1, 96.5% met CCOq control criteria, whereas none with scores ≥4 were classified as controlled. Patients were categorized as good (0–1), partial (2–3), or poor control (≥4). Time to composite event differed significantly across groups (p < 0.001), with RADAR remaining an independent predictor after adjustment. Predictive accuracy (C-statistic) was 0.697 (adjusted) and 0.713 (unadjusted).

Conclusion: The RADAR score effectively predicts clinical risk and health status, offering a practical tool for monitoring COPD and guiding clinical decisions.

Key words:
COPD
control
score
exacerbations
mortality
monitoring
Full text is only available in PDF
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?